Advanced Biomed vs YD Bio
ADVB and YDES side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADVB and YDES compare
Advanced Biomed scores higher on the StockData Score (8 against 5 for YD Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADVB | YDES |
|---|---|---|
| Size and price | ||
| Market cap | $4.2M | – |
| Share price | $2.53 | $4.88 |
| Change, 1 year | −72.0% | −44.8% |
| Change, 5 years | – | −52.0% |
| Beta (5Y) | 0.81 | 0.10 |
| Employees | 12 | 13 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 2 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 0.4× | – |
| P/B | 0.4× | – |
| Growth | ||
| Revenue growth (TTM) | – | 16.9% |
| Profitability | ||
| Gross margin | – | 28.1% |
| Operating margin | – | −883% |
| Net margin | – | −1393% |
| FCF margin | – | −1347% |
| Return on equity | 85.0% (better) | −174% |
| Return on invested capital | – | −130% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 8.09 (better) | 5.23 |
| Altman Z-score | 1.13 | – |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by insiders | 0.00% | 92.8% |
| Insider net buying, 12 months | – | $129K |
| Short interest, % of float | 0.68% | – |
Go deeper
- ADVB stock overview
- ADVB income statement
- ADVB valuation and score
- YDES stock overview
- YDES income statement
- YDES valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.